M. Jarman

Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase)

B. Haynes, M. Jarman, P. Goddard, 1994, The Journal of Steroid Biochemistry and Molecular Biology.

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.

M. Rowlands, M. Jarman, S. E. Barrie, 1995, Journal of medicinal chemistry.

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors

M. Dowsett, B. Haynes, M. Jarman, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Idoxifene: report of a phase I study in patients with metastatic breast cancer.

M. Dowsett, R. Coombes, I. Judson, 1995, Cancer research.

A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism.

M. Jarman, G. A. Potter, R. Mccague, 1994, Carcinogenesis.

Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.

G. Leclercq, G. Blackburn, M. Jarman, 1989, Journal of medicinal chemistry.

The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.

M. Dowsett, R. A’Hern, S. Riddler, 1997, British Journal of Cancer.

Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

M. Dowsett, R. Coombes, Y. Luqmani, 1991, Cancer research.